A new in vitro study reported that 1,5-pentanediamine—detectable in blood from patients colonized with carbapenem-resistant Klebsiella pneumoniae—can weaken CD19 CAR-T cell function. Researchers from Tongji Hospital and Tongji Medical College of Huazhong University of Science and Technology showed the metabolite undermines CAR-T cells in lab conditions. The mechanism points to a previously underappreciated variable in CAR-T outcomes: host–microbiome chemistry during treatment. If metabolite exposure is clinically relevant, it could complicate patient selection, infection-management strategies, or future CAR-T manufacturing and adjunct therapies. While the work is preclinical, it provides an actionable hypothesis for translational teams to evaluate metabolite levels, colonization status, and functional correlations in patient cohorts.